Pro Medicus shares higher on $30m contract win

Good news is lifting this high-flying stock on Monday. Let's dig deeper into it.

| More on:
A young man working from home sits at his home office desk holding a cup of tea and looking out the window

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Limited (ASX: PME) shares are starting the week on a positive note.

In morning trade, the health imaging technology company's shares are up 1.5% to $251.90.

What's happening?

Investors have been buying the high-flying ASX tech stock on Monday following the release of an announcement.

According to the release, the company has signed a $30 million, seven-year contract with Duly Health and Care (DHC). It is the largest independent, multi-specialty physician-directed medical group in the Midwest of the United States.

It notes that the DHC brand includes DuPage Medical Group, Quincy Medical Group, and The South Bend Clinic. It supports over 40 radiologists, 1,000 physicians, and 150 outpatient clinics.

Based on a transactional licensing model, the contract will see Pro Medicus' cloud-engineered Visage 7 Enterprise Imaging Platform (Visage 7), including Visage 7 Open Archive and Visage 7 Workflow modules, implemented throughout DHC. This will provide a unified diagnostic imaging platform.

Management expects the migration from DHC's legacy PACS archive and vendor neutral archive to Visage 7 Open Archive to complete during the second quarter of the 2025 calendar year. Planning for the rollout is to commence immediately and will be based on Visage's proven cloud-based implementation process.

Management commentary

Pro Medicus CEO, Dr Sam Hupert, was pleased with the deal for a number of reasons. He said:

Duly Health and Care is an important deal for us as they are in the private radiology/outpatient space, an area of the market where we are starting to see increased opportunity. They also join a long list of Visage 7 clients to opt for a fully cloud-engineered solution, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

Our pipeline remains strong and spans all market segments including academic medical centers, IDNs and the private/teleradiology market. As has been the case with many of our recent contracts, this deal is for our "full stack" comprising all three Visage products namely viewer, workflow and archive, a trend we see continuing.

Should you buy Pro Medicus shares?

Goldman Sachs is a fan of the company and recently put a buy rating and $278.00 price target on its shares.

While the broker acknowledges that its shares are not cheap, it feels they deserve this premium valuation. It said:

PME is not cheap, trading on 114x FY26E EV/EBITDA, but we highlight its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. Additionally, with a focus on the US regulatory outlook, we believe MedTech is increasingly being evaluated as a safe haven within healthcare as it is generally more insulated from impending policy volatility.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Technology Shares

WiseTech share price higher on big news

This tech stock has found its new leader.

Read more »

Man holding a calculator with Australian dollar notes, symbolising dividends.
Technology Shares

$10,000 invested in DroneShield shares 5 years ago is now worth…

You might be laughing all the way to the bank if you had done this.

Read more »

Happy woman working on a laptop.
Technology Shares

Up 60% since April, why this $40 billion ASX 200 tech stock remains a 'compelling buy' today

A leading expert believes this $40 billion ASX 200 tech stock has a lengthy growth runway ahead of it yet.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Technology Shares

DroneShield shares sink 7% despite big news

Let's see what's going on with this market darling on Thursday.

Read more »

A man activates an arrow shooting up into a cloud sign on his iPad.
Technology Shares

Up 25% since April, is it too late to buy Xero shares today?

A leading expert gives his verdict on the growth outlook for Xero shares.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Technology Shares

2 amazing ASX tech shares I wish I'd bought last year

These tech companies are among the world’s best companies.

Read more »

A man in a business suit and tie places three wooden blocks with the numbers 1, 2, and 3 on them on top of each other.
Broker Notes

3 reasons to buy this booming ASX All Ords tech stock today

A leading broker forecasts more gains to come from this surging ASX All Ords tech stock.

Read more »

Man ponders a receipt as he looks at his laptop.
Technology Shares

Brokers rerate 3 leading ASX 200 tech stocks

Experts reveal their ratings on the ASX 200 tech sector's three biggest companies.

Read more »